1. |
Konstantinos H. Prostate cancer in the elderly. Int Urol Nephrol 2005; 37: 797-806.
|
|
2.Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
|
|
3.Chen YC, Chuang CK, Hsieh ML, et al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan. Urology 2007; 70: 101-5.
|
4. |
Sridharan S, Dal Pra A, Catton C, et al. Locally advanced prostate cancer: current controversies and optimisation opportunities. Clin Oncol (R Coll Radiol) 2013; 25: 499-505.
|
|
5.Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6.
|
6. |
van den Ouden D, Hop WC, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160: 1392-7.
|
7. |
Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 444-52.
|
|
8.Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59: 1352-9.
|
|
9.Nickers P, Coppens L, de Leval J, et al. 192 Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial. Radiother Oncol 2006; 79: 329-34.
|
10 |
Pellizzon AC, Salvajoli J, Novaes P, et al. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 2008; 5: 113-20.
|
11 |
Stock RG, Cesaretti JA, Hall SJ, et al. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radio- therapy and hormonal therapy. BJU Int 2009; 104: 1631-6.
|
|
12.Davis BJ, Horwitz EM, Lee WR, et al. American Brachy- therapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012; 11: 6-19.
|
|
13.Mohler JL, Armstrong AJ, Bahnson B, et al. Prostate cancer, Version 3. 2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 1081-7.
|
14 |
Sylvester J, Blasko JC, Grimm P, et al. Interstitial implantation techniques in prostate cancer. J Surg Oncol 1997; 66: 65-75.
|
15 |
American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41.
|
16 |
Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009; 101: 1280-3.
|
17 |
Pilepich MV, Winter K, Lawton CA, et al. Androgen sup- pression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90.
|
18 |
Pistis F, Guedea F, Pera J, et al. External beam radio- therapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy 2010; 9:15-22.
|
|
19.Hsu IC, Cabrera AR, Weinberg V, et al. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachy- therapy 2005; 4: 202-6.
|
20 |
Carpenter TJ, Forsythe K, Kao J, et al. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy 2011; 10: 261-8.
|
|
21.Shilkrut M, McLaughlin PW, Merrick GS, et al. Treatment outcomes in very high-risk prostate cancer treated by dose-escalated and combined-modality radiation therapy. Am J Clin Oncol 2014 Feb 10. [2015-01-01].
|
22 |
Fioriti D, Mischitelli M, Di Monaco F, et al. Cancer stem cells in prostate adenocarcinoma: a target for new anticancer strategies. J Cell Physiol 2008; 216: 571-5.
|
|
23.Ishiyama H, Satoh T, Kitano M, et al. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res 2014; 55: 509-17.
|
24 |
Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachy- therapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1048-55.
|